Caroline Deckmann Nicoletti
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Caroline Deckmann Nicoletti has a total of 34 co-authors. Here are the top co-authors by number of shared publications:
- Vitor Francisco Ferreira
Programa de Pós-Graduação em Ciências Aplicadas a Produtos para a Saúde, Faculdade de Farmácia, Universidade Federal Fluminense, Niterói 24241-000, RJ, Brazil
6 shared publications - Debora Omena Futuro
Universidade Federal Fluminense, Departamento de Tecnologia Farmacêutica, Faculdade de Farmácia, Brazil
3 shared publications - Patricia Garcia Ferreira
Department of Pharmacy and Pharmaceutical Administration, Universidade Federal Fluminense, Niterói, Rio de Janeiro, Brazil
3 shared publications - Bárbara Verena Dias Galvão
Department of Biophysics and Biometry, Rio de Janeiro State University, Rio de Janeiro, Brazil
2 shared publications - Carlos Fernando Araujo-Lima
Laboratory of Environmental Mutagenesis, Department of Biophysics and Biometry, Rio de Janeiro State University (UERJ), Rio de Janeiro 20551-030, RJ, Brazil
2 shared publications - Fernando de Carvalho da Silva
Universidade Federal Fluminense
2 shared publications
Latest Publications
- Open Access
- 16 October 2026
- Published by Springer Nature in BioMetals
- p. 1-19
Toxicogenetic profiling of an antifungal lawsone silver salt: in silico and in vitro analysis in 2D and 3D mammalian models
The development of novel metal-based antifungals requires rigorous characterization of their toxicological mechanisms to ensure patient safety. This study investigated the toxicogenetic profile and cellular interactions of lawsone silver salt (LSS), a compound with established activity against Sporothrix spp. and emerging multidrug-resistant pathogens. Antifungal efficacy was confirmed against planktonic Aspergillus fumigatus , Candida albicans , and C. auris (MIC 1.45–23.2 µM), with significant anti-biofilm activity against C. albicans (185.9 µM) and A. fumigatus (92.9 µM). In silico ADMET modeling predicted high oral bioavailability and blood–brain barrier permeability, despite the genotoxicity alerts. Experimentally, LSS (0.005–50 µg/plate) was non-mutagenic in the Salmonella /microsome assay (TA1535, TA97a, TA98, TA100, and TA102), regardless of the metabolic activation. However, LSS (0.5–500 µM) induced significant genomic instability in HepG2 cells. The micronucleus assay revealed a dose-dependent increase in micronuclei, nucleoplasmic bridges, and nuclear buds, indicating clastogenic and aneugenic effects. Comparative cytotoxicity was evaluated in BALB/3T3 fibroblasts using 2D monolayers and scaffold-based 3D models (0.005–5000 µM). In 2D cultures, LSS exhibited potent cytotoxicity (CC 50 : 2.7–19.9 µM). Crucially, the 3D microenvironment significantly attenuated these effects (CC 50 : 1,797–1,919 µM), suggesting a markedly higher safety margin in physiologically relevant tissue architectures. These findings demonstrate that while LSS induces chromosomal damage in human cells, its toxicity is fundamentally modulated by cellular organization, providing essential data for risk assessment and therapeutic optimization of naphthoquinone derivatives.
- 16 October 2026
- Published by Springer Nature in BioMetals
- p. 1-19
Open AccessToxicogenetic profiling of an antifungal lawsone silver salt: in silico and in vitro analysis in 2D and 3D mammalian models
The development of novel metal-based antifungals requires rigorous characterization of their toxicological mechanisms to ensure patient safety. This study investigated the toxicogenetic profile and cellular interactions of lawsone silver salt (LSS), a compound with established activity against Sporothrix spp. and emerging multidrug-resistant pathogens. Antifungal efficacy was confirmed against planktonic Aspergillus fumigatus , Candida albicans , and C. auris (MIC 1.45–23.2 µM), with significant anti-biofilm activity against C. albicans (185.9 µM) and A. fumigatus (92.9 µM). In silico ADMET modeling predicted high oral bioavailability and blood–brain barrier permeability, despite the genotoxicity alerts. Experimentally, LSS (0.005–50 µg/plate) was non-mutagenic in the Salmonella /microsome assay (TA1535, TA97a, TA98, TA100, and TA102), regardless of the metabolic activation. However, LSS (0.5–500 µM) induced significant genomic instability in HepG2 cells. The micronucleus assay revealed a dose-dependent increase in micronuclei, nucleoplasmic bridges, and nuclear buds, indicating clastogenic and aneugenic effects. Comparative cytotoxicity was evaluated in BALB/3T3 fibroblasts using 2D monolayers and scaffold-based 3D models (0.005–5000 µM). In 2D cultures, LSS exhibited potent cytotoxicity (CC 50 : 2.7–19.9 µM). Crucially, the 3D microenvironment significantly attenuated these effects (CC 50 : 1,797–1,919 µM), suggesting a markedly higher safety margin in physiologically relevant tissue architectures. These findings demonstrate that while LSS induces chromosomal damage in human cells, its toxicity is fundamentally modulated by cellular organization, providing essential data for risk assessment and therapeutic optimization of naphthoquinone derivatives.
- Open Access
- 18 August 2026
- Published by JMIR Publications Inc. in JMIR Research Protocols
- Vol. 15, e98251
AI Applied to Formulation Design, Process Optimization, and Quality Control in 3D Printed Drug Products: Protocol for a Scoping Review
Background: 3D printing is an advanced, computer-aided design (CAD)–guided, layer-by-layer manufacturing technology with strong potential for producing patient-specific drug products. Integrating AI with pharmaceutical 3D printing can accelerate formulation development, improve process robustness and quality, and enable efficient personalization across the preprinting, printing, and postprinting stages. However, evidence remains dispersed across technologies, dosage forms, and AI approaches, making it difficult to obtain a comprehensive understanding of current research and knowledge gaps. Objective: This scoping review protocol aims to map and characterize how AI has been applied to the formulation design, process optimization, and quality control of 3D printed drug products across the preprinting, printing, and postprinting stages. Methods: This review will follow the Joanna Briggs Institute (JBI) methodology and the PRISMA-ScR (Preferred Reporting Items for Systematic Reviews and Meta-Analyses Extension for Scoping Reviews) checklist and guidelines for scoping reviews. The following databases and resources will be searched: MEDLINE (PubMed), Scopus, and Web of Science. Screening, data extraction, and data analysis will be conducted by 2 reviewers independently. Findings will be presented in summary tables and a narrative synthesis. Results: The protocol and search strategy were finalized in April 2026, and the review was registered on the Open Science Framework (OSF). Literature searches are scheduled to be conducted between May 2026 and June 2026, followed by title and abstract screening and full-text assessment between June 2026 and August 2026. Data extraction and narrative synthesis are expected to be completed by September 2026. The final scoping review is expected to be submitted for publication in the fourth quarter of 2026. Conclusions: This protocol outlines a scoping review to map the use of AI in the formulation design, process optimization, and quality control of 3D printed drug products, and summarize current research and identify areas for future investigation. Trial Registration: Open Science Framework 10.17605/OSF.IO/2R8ED; https://osf.io/2r8ed/overview International Registered Report Identifier (IRRID): PRR1-10.2196/98251
- 18 August 2026
- Published by JMIR Publications Inc. in JMIR Research Protocols
- Vol. 15, e98251
Open AccessAI Applied to Formulation Design, Process Optimization, and Quality Control in 3D Printed Drug Products: Protocol for a Scoping Review
Background: 3D printing is an advanced, computer-aided design (CAD)–guided, layer-by-layer manufacturing technology with strong potential for producing patient-specific drug products. Integrating AI with pharmaceutical 3D printing can accelerate formulation development, improve process robustness and quality, and enable efficient personalization across the preprinting, printing, and postprinting stages. However, evidence remains dispersed across technologies, dosage forms, and AI approaches, making it difficult to obtain a comprehensive understanding of current research and knowledge gaps. Objective: This scoping review protocol aims to map and characterize how AI has been applied to the formulation design, process optimization, and quality control of 3D printed drug products across the preprinting, printing, and postprinting stages. Methods: This review will follow the Joanna Briggs Institute (JBI) methodology and the PRISMA-ScR (Preferred Reporting Items for Systematic Reviews and Meta-Analyses Extension for Scoping Reviews) checklist and guidelines for scoping reviews. The following databases and resources will be searched: MEDLINE (PubMed), Scopus, and Web of Science. Screening, data extraction, and data analysis will be conducted by 2 reviewers independently. Findings will be presented in summary tables and a narrative synthesis. Results: The protocol and search strategy were finalized in April 2026, and the review was registered on the Open Science Framework (OSF). Literature searches are scheduled to be conducted between May 2026 and June 2026, followed by title and abstract screening and full-text assessment between June 2026 and August 2026. Data extraction and narrative synthesis are expected to be completed by September 2026. The final scoping review is expected to be submitted for publication in the fourth quarter of 2026. Conclusions: This protocol outlines a scoping review to map the use of AI in the formulation design, process optimization, and quality control of 3D printed drug products, and summarize current research and identify areas for future investigation. Trial Registration: Open Science Framework 10.17605/OSF.IO/2R8ED; https://osf.io/2r8ed/overview International Registered Report Identifier (IRRID): PRR1-10.2196/98251
- Open Access
- 14 April 2026
- Published by JMIR Publications Inc. in JMIR Preprints
AI Applied to Formulation Design, Process Optimization, and Quality Control in 3D Printed Drug Products: Protocol for a Scoping Review (Preprint)
BACKGROUND 3D printing is an advanced, computer-aided design (CAD)–guided, layer-by-layer manufacturing technology with strong potential for producing patient-specific drug products. Integrating AI with pharmaceutical 3D printing can accelerate formulation development, improve process robustness and quality, and enable efficient personalization across the preprinting, printing, and postprinting stages. However, evidence remains dispersed across technologies, dosage forms, and AI approaches, making it difficult to obtain a comprehensive understanding of current research and knowledge gaps. OBJECTIVE This scoping review protocol aims to map and characterize how AI has been applied to the formulation design, process optimization, and quality control of 3D printed drug products across the preprinting, printing, and postprinting stages. METHODS This review will follow the Joanna Briggs Institute (JBI) methodology and the PRISMA-ScR (Preferred Reporting Items for Systematic Reviews and Meta-Analyses Extension for Scoping Reviews) checklist and guidelines for scoping reviews. The following databases and resources will be searched: MEDLINE (PubMed), Scopus, and Web of Science. Screening, data extraction, and data analysis will be conducted by 2 reviewers independently. Findings will be presented in summary tables and a narrative synthesis. RESULTS The protocol and search strategy were finalized in April 2026, and the review was registered on the Open Science Framework (OSF). Literature searches are scheduled to be conducted between May 2026 and June 2026, followed by title and abstract screening and full-text assessment between June 2026 and August 2026. Data extraction and narrative synthesis are expected to be completed by September 2026. The final scoping review is expected to be submitted for publication in the fourth quarter of 2026. CONCLUSIONS This protocol outlines a scoping review to map the use of AI in the formulation design, process optimization, and quality control of 3D printed drug products, and summarize current research and identify areas for future investigation. CLINICALTRIAL Open Science Framework 10.17605/OSF.IO/2R8ED; https://osf.io/2r8ed/overview INTERNATIONAL REGISTERED REPORT PRR1-10.2196/98251
- 14 April 2026
- Published by JMIR Publications Inc. in JMIR Preprints
Open AccessAI Applied to Formulation Design, Process Optimization, and Quality Control in 3D Printed Drug Products: Protocol for a Scoping Review (Preprint)
BACKGROUND 3D printing is an advanced, computer-aided design (CAD)–guided, layer-by-layer manufacturing technology with strong potential for producing patient-specific drug products. Integrating AI with pharmaceutical 3D printing can accelerate formulation development, improve process robustness and quality, and enable efficient personalization across the preprinting, printing, and postprinting stages. However, evidence remains dispersed across technologies, dosage forms, and AI approaches, making it difficult to obtain a comprehensive understanding of current research and knowledge gaps. OBJECTIVE This scoping review protocol aims to map and characterize how AI has been applied to the formulation design, process optimization, and quality control of 3D printed drug products across the preprinting, printing, and postprinting stages. METHODS This review will follow the Joanna Briggs Institute (JBI) methodology and the PRISMA-ScR (Preferred Reporting Items for Systematic Reviews and Meta-Analyses Extension for Scoping Reviews) checklist and guidelines for scoping reviews. The following databases and resources will be searched: MEDLINE (PubMed), Scopus, and Web of Science. Screening, data extraction, and data analysis will be conducted by 2 reviewers independently. Findings will be presented in summary tables and a narrative synthesis. RESULTS The protocol and search strategy were finalized in April 2026, and the review was registered on the Open Science Framework (OSF). Literature searches are scheduled to be conducted between May 2026 and June 2026, followed by title and abstract screening and full-text assessment between June 2026 and August 2026. Data extraction and narrative synthesis are expected to be completed by September 2026. The final scoping review is expected to be submitted for publication in the fourth quarter of 2026. CONCLUSIONS This protocol outlines a scoping review to map the use of AI in the formulation design, process optimization, and quality control of 3D printed drug products, and summarize current research and identify areas for future investigation. CLINICALTRIAL Open Science Framework 10.17605/OSF.IO/2R8ED; https://osf.io/2r8ed/overview INTERNATIONAL REGISTERED REPORT PRR1-10.2196/98251
- 1 July 2024
- Published by Bentham Science Publishers Ltd. in Current Organic Chemistry
- Vol. 28 (13) , 991-1005
Innovations in Treating Sporotrichosis: Drug Repurposing and Lead Compound Synthesis
Sporotrichosis, recognized by the World Health Organization (WHO) as a neglected tropical disease and classified among significant fungal health concerns, remains both underestimated and underreported. There is a profound impact of sporotrichosis on public health, affecting both humans and domestic animals. The causative agents are fungi within the Sporothrix genus, primarily transmitted through traumatic exposure to contaminated soil, plants, decomposing materials, or through scratches from infected animals, notably cats. While sporotrichosis is a global concern, its prevalence is particularly noteworthy in tropical and subtropical regions. The limited treatment options for sporotrichosis, with itraconazole as the preferred choice, underscore the challenges posed by fungal infections. Issues such as toxicity and drug resistance further complicate effective management. Consequently, this review aims to elucidate key objectives: identification of novel synthetic compounds revealed in the literature, highlighting ongoing efforts to develop new treatments against sporotrichosis, examining promising anti-sporothrix natural products, and providing an overview of endeavors to repurpose approved drugs. The key findings from the study underscore the urgent need for diversified and effective drugs for the treatment of Sporotrichosis.
- 1 July 2024
- Published by Bentham Science Publishers Ltd. in Current Organic Chemistry
- Vol. 28 (13) , 991-1005
Innovations in Treating Sporotrichosis: Drug Repurposing and Lead Compound Synthesis
Sporotrichosis, recognized by the World Health Organization (WHO) as a neglected tropical disease and classified among significant fungal health concerns, remains both underestimated and underreported. There is a profound impact of sporotrichosis on public health, affecting both humans and domestic animals. The causative agents are fungi within the Sporothrix genus, primarily transmitted through traumatic exposure to contaminated soil, plants, decomposing materials, or through scratches from infected animals, notably cats. While sporotrichosis is a global concern, its prevalence is particularly noteworthy in tropical and subtropical regions. The limited treatment options for sporotrichosis, with itraconazole as the preferred choice, underscore the challenges posed by fungal infections. Issues such as toxicity and drug resistance further complicate effective management. Consequently, this review aims to elucidate key objectives: identification of novel synthetic compounds revealed in the literature, highlighting ongoing efforts to develop new treatments against sporotrichosis, examining promising anti-sporothrix natural products, and providing an overview of endeavors to repurpose approved drugs. The key findings from the study underscore the urgent need for diversified and effective drugs for the treatment of Sporotrichosis.
- 8 March 2022
- Published by Springer Nature in Brazilian Journal of Microbiology
- Vol. 53 (2) , 749-758
A novel naphthoquinone derivative shows selective antifungal activity against Sporothrix yeasts and biofilms
Sporotrichosis is a subcutaneous mycosis that affects humans and animals, with few therapeutic options available in the pharmaceutical market. We screened the in vitro antifungal activity of fourteen 1,4-naphthoquinones derivative compounds against Sporothrix brasiliensis and Sporothrix schenckii, the main etiological agents of sporotrichosis in Latin America. The most active compound was selected for further studies exploring its antibiofilm activity, effects on yeast morphophysiology, interaction with itraconazole, and selectivity to fungal cells. Among the fourteen 1,4-naphthoquinones tested, naphthoquinone 5, a silver salt of lawsone, was the most active compound. Naphthoquinone 5 was able to inhibit Sporothrix biofilms and induced ROS accumulation, mitochondrial disturbances, and severe plasmatic membrane damage in fungal cells. Furthermore, naphthoquinone 5 was ten times more selective towards fungal cells than fibroblast, and the combination of itraconazole with naphthoquinone 5 improved the inhibitory activity of the azole. Combined, the data presented here indicate that the silver salt naphthoquinone 5 exerts promising in vitro activity against the two main agents of sporotrichosis with important antibiofilm activity and a good toxicity profile, suggesting it is a promising molecule for the development of a new family of antifungals.
- 8 March 2022
- Published by Springer Nature in Brazilian Journal of Microbiology
- Vol. 53 (2) , 749-758
A novel naphthoquinone derivative shows selective antifungal activity against Sporothrix yeasts and biofilms
Sporotrichosis is a subcutaneous mycosis that affects humans and animals, with few therapeutic options available in the pharmaceutical market. We screened the in vitro antifungal activity of fourteen 1,4-naphthoquinones derivative compounds against Sporothrix brasiliensis and Sporothrix schenckii, the main etiological agents of sporotrichosis in Latin America. The most active compound was selected for further studies exploring its antibiofilm activity, effects on yeast morphophysiology, interaction with itraconazole, and selectivity to fungal cells. Among the fourteen 1,4-naphthoquinones tested, naphthoquinone 5, a silver salt of lawsone, was the most active compound. Naphthoquinone 5 was able to inhibit Sporothrix biofilms and induced ROS accumulation, mitochondrial disturbances, and severe plasmatic membrane damage in fungal cells. Furthermore, naphthoquinone 5 was ten times more selective towards fungal cells than fibroblast, and the combination of itraconazole with naphthoquinone 5 improved the inhibitory activity of the azole. Combined, the data presented here indicate that the silver salt naphthoquinone 5 exerts promising in vitro activity against the two main agents of sporotrichosis with important antibiofilm activity and a good toxicity profile, suggesting it is a promising molecule for the development of a new family of antifungals.
- 21 March 2020
- Published by Springer Nature in Journal of Bioenergetics and Biomembranes
- Vol. 52 (3) , 185-197
Synthesis and biological evaluation of β-lapachone and nor-β-lapachone complexes with 2-hydroxypropyl-β-cyclodextrin as trypanocidal agents
We study βLAP and its derivative nor-β-Lapachone (NβL) complexes with 2-hydroxypropyl-β-cyclodextrin to increase the solubility and bioavailability. The formation of true inclusion complexes between βLAP or NβL in 2-HP-β-CD in solid solution was characterization by FT-IR, DSC, powder X-ray was and was confirmed by one- and two-dimensional 1H NMR experiments. Additionally, the biological activities of βLAP, NβL, ICβLAP, and ICNβL were investigated through trypanocidal assays with T. cruzi and cytotoxicity studies with mouse peritoneal macrophages. Originally, we tested these complexes against T. cruzi viability and observed higher biological activities and lower cytotoxicity when compared to βLAP and NβL. Thus, the complexation of βLAP and NβL with 2-HP-β-CD increases the drug solubility, in addition vectorization was observed, increasing the biological activity against epimastigotes and trypomastigotes T. cruzi forms. Reduced the toxicity of the compounds against mammalian cells. In addition, the selectivity indices higher of the inclusion complexes comparing to substance free and those of benznidazole.
- 21 March 2020
- Published by Springer Nature in Journal of Bioenergetics and Biomembranes
- Vol. 52 (3) , 185-197
Synthesis and biological evaluation of β-lapachone and nor-β-lapachone complexes with 2-hydroxypropyl-β-cyclodextrin as trypanocidal agents
We study βLAP and its derivative nor-β-Lapachone (NβL) complexes with 2-hydroxypropyl-β-cyclodextrin to increase the solubility and bioavailability. The formation of true inclusion complexes between βLAP or NβL in 2-HP-β-CD in solid solution was characterization by FT-IR, DSC, powder X-ray was and was confirmed by one- and two-dimensional 1H NMR experiments. Additionally, the biological activities of βLAP, NβL, ICβLAP, and ICNβL were investigated through trypanocidal assays with T. cruzi and cytotoxicity studies with mouse peritoneal macrophages. Originally, we tested these complexes against T. cruzi viability and observed higher biological activities and lower cytotoxicity when compared to βLAP and NβL. Thus, the complexation of βLAP and NβL with 2-HP-β-CD increases the drug solubility, in addition vectorization was observed, increasing the biological activity against epimastigotes and trypomastigotes T. cruzi forms. Reduced the toxicity of the compounds against mammalian cells. In addition, the selectivity indices higher of the inclusion complexes comparing to substance free and those of benznidazole.
- 14 September 2019
- Published by Springer Nature in Medicinal Chemistry Research
- Vol. 28 (12) , 2109-2117
Synthesis of dehydro-α-lapachones, α- and β-lapachones, and screening against cancer cell lines
- 14 September 2019
- Published by Springer Nature in Medicinal Chemistry Research
- Vol. 28 (12) , 2109-2117
Synthesis of dehydro-α-lapachones, α- and β-lapachones, and screening against cancer cell lines